B-Myb is a cell-cycle regulated transcription factor which is implicated in cell proliferation and has an essential role in early embryonic development. In this study we examined the functions of B-Myb required to overcome G1 arrest in Saos-2 cells induced by the retinoblastoma-related p107 protein. Our results demonstrated that this activity was independent of B-Myb transactivation function, but correlated with its capacity to form an in vivo complex with p107. A large proportion of B-Myb formed complexes with p107 in cotransfected cells, however, B-Myb bound weakly to the related p130 protein and not at all to pRb. In contrast to the E2F transcription factors, which bind the p107 C-terminal pocket domain, B-Myb recognizes an N-terminal p107 region which overlaps the larger cyclin-binding domain. B-Myb and cyclin A2 formed mutually exclusive complexes with p107, and B-Myb enhanced the activity of co-transfected cyclin E kinase activity, implying that B-Myb affects the cell cycle by preventing sequestration of active cyclin/cdk2 complexes. This study defines a novel function of B-Myb and further suggests that the p107 N-terminus provides an interaction domain for transcription factors involved in cell cycle control.
Introduction
In common with the related c-Myb onco-protein and A-Myb, the B-Myb transcription factor is implicated in regulating cell growth and development (reviewed in Sala and Watson, 1999; Saville and Watson, 1998a) . Bmyb expression is transcriptionally repressed during G0 and G1 phases of the cell cycle by p107 and p130 E2F complexes, and is transcribed maximally during early S phase (Hurford et al., 1997; Lam et al., 1994; Lam and Watson, 1993 ). In addition to this level of control, the B-Myb protein undergoes a specific post-translational modification during S phase (Robinson et al., 1996) which results from phosphorylation by the cyclin A2/ cdk2 protein kinase (Ansieau et al., 1997; Bartsch et al., 1999; Johnson et al., 1999b; Lane et al., 1997; Sala et al., 1997; Saville and Watson, 1998b; Ziebold et al., 1997) . The major cyclin A2/cdk2 phosphorylation sites map within the C-terminal half of B-Myb, and lie within or adjacent to a negative-regulatory domain (NRD) which restricts B-Myb DNA-binding and transactivation activities (Ansieau et al., 1997; Lane et al., 1997; Watson et al., 1993; Ziebold et al., 1997) . Significantly, ectopic expression of cyclin A2 markedly enhances B-Myb transactivation activity (Ansieau et al., 1997; Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) , suggesting that phosphorylation counteracts the inhibitory effect of the NRD.
The findings that transcriptional and post-translational mechanisms combine to direct high levels of hyperactivated B-Myb protein to S phase strongly suggest that B-Myb plays a critical role at this stage of the cell cycle. B-myb expression is ubiquitous within proliferating cell lines, suggesting that this requirement for B-Myb function might be common to a wide spectrum of cell types. In support of this notion, B-myb antisense oligonucleotides were found to inhibit proliferation of certain myeloid, lymphoid, glioblastoma, fibroblast and neuroblastoma cell lines (Arsura et al., 1992; Lin et al., 1994; Raschella et al., 1995; Sala and Calabretta, 1992) , albeit not all studies were able to demonstrate these effects (Robinson et al., 1996) . Conversely, constitutive expression of B-myb prevented cell cycle arrest associated with culture of BALB/c 3T3 fibroblasts in low serum-containing medium (Sala and Calabretta, 1992) or IL-6-induced differentiation of M1 myeloid leukaemia cells (Bies et al., 1996) . An essential and ubiquitious role for B-Myb is also suggested by the findings that B-myb is expressed throughout mammalian embryogenesis (Sitzmann et al., 1996) , and that homozygous gene knockout mutants died early in development at around E4.5 -E6.5 (Tanaka et al., 1999) .
Although these studies indicate an essential role for B-Myb in cell growth, neither the functions required nor the stage of the cell cycle at which B-Myb acts have been definitively established. Some studies suggest, however, that ectopic expression of B-myb can promote transition of cells from the G1 to the S phase of the cell cycle, most notably in cell lines in which the G1 checkpoint was activated by p53 or p107 (Lin et al., 1994; Sala et al., 1996a) . This conclusion is supported by evidence that overexpression of B-myb was sufficient by itself to promote entry of T98G glioblastoma cells into S phase (Sala et al., 1996a) , whilst in the U-2 OS osteosarcoma cell line B-Myb acted synergistically with cyclin A2 to induce S phase (Lane et al., 1997) . Although it has been tacitly assumed that promotion of cell proliferation by BMyb reflects its role as a transcriptional activator, a transactivation domain mutant (MUT-7) was still partially active in overcoming p53-induced growth arrest in Saos-2 cells (Lin et al., 1994) . Moreover, we recently found that the ability of ectopically expressed B-Myb to overcome a p107-induced G1 arrest was dependent upon a direct physical interaction between these proteins (Bessa et al., 2001a) , and notably a transcriptionally activated B-Myb protein was deficient in abrogating p107 activity. We have extended these observations by mapping the interaction domains between B-Myb and p107, and by examining whether B-Myb transactivation activity is required to abrogate the p107 block. Our findings reveal that B-Myb binds to an N-terminal p107 domain that overlaps with the cyclin-binding domain.
Results

B-Myb transactivation activity is not required to overcome a p107-mediated G1 block
To explore whether B-Myb transactivation function is required to overcome a p107-induced G1 arrest, we first introduced a number of small deletions into the B-Myb Acidic Region (AR: aa 205 -308), which constitutes the major transactivation domain (Nakagoshi et al., 1993) . Notably, the B-Myb AR is quite distinct from the c-Myb transactivation domain, which shares a weakly acidic character but little if any homology. Additional deletions were also introduced downstream of the AR coding sequence in a region that is highly conserved between mouse and human BMyb (aa 333 -388). The transactivation activities of this set of mutants ( Figure 1a ) were then compared with wild-type B-Myb by transient transfection in U-2 OS cells using the pT81luc 3xA luciferase reporter (Ness et al., 1989) . In this cell line, transfected B-Myb is partially phosphorylated by endogenous cyclin A2/ cdk2 (Saville and Watson, 1998b) , resulting in enhanced transactivation activity. Deletion of the most N-terminal AR sequence (as in B-MybD205 -243) abolished transactivation activity almost completely, whereas deletion of other segments of the AR and the downstream sequences resulted in retention of residual transactivation activity (Figure 1b) . Notably, some mutants (i.e. B-MybD244 -288) and BMybD289 -308) demonstrated enhanced activity (Figure 1b) .
We next compared the abilities of wt B-Myb and the B-Myb mutants to overcome a p107-mediated G1 arrest in Saos-2 cells, with the goal of testing whether this cell cycle effect correlated with transactivation function. In this assay, parallel cultures received the BMyb expression constructs (or an empty vector) either with or without cotransfected p107, and the percentage of cells in G1 was assessed by flow cytometry using a CD20 marker to discriminate the transfected cells ( Figure 1c ). In the control vector transfected cells, the percentage of cells in G1 was increased from 51 to 72% by p107 cotransfection (Figure 1c ). It is notable that in wt B-Myb transfected cells the comparable figures were 50 and 54%, indicating that G1 arrest induced by p107 was largely abolished by ectopic BMyb expression. Importantly, the only B-Myb mutant which significantly counteracted p107-mediated G1 arrest was B-MybD205 -243, which limited the increase in G1 from 49 to 57% (Figure 1c) . Although the effect of B-MybD205 -243 on the cell cycle block was not as pronounced as observed with wt B-Myb, this effect was seen consistently. Remarkably, transactivation by BMybD205 -243 was found to be virtually abolished ( Figure 1b) . In contrast, transcriptionally activated mutants such as B-MybD289 -308 were unable to overcome the p107 G1 block. These results therefore strongly suggest that the ability of B-Myb to counteract p107 G1 arrest is dissociated from its transactivation function.
Complex formation between B-Myb and p107 correlates with abrogation of the p107-mediated G1 block
Previous studies have shown that B-Myb complexes with p107 in vivo (Sala et al., 1996b; Sala and Watson, 1999) , and we therefore asked whether this interaction could account for the ability of B-Myb and BMybD205 -243 to overcome the p107-mediated G1 block. To address this question, Saos-2 cells were cotransfected with a p107 plasmid together with plasmids encoding either wt B-Myb or the AR deletion mutants. Lysates were made from these cells 2 days post-transfection; 10% of the lysate was retained and the remainder was split into two fractions which were subjected to immunoprecipitation (IP) using either a Cterminal p107 antibody or a control serum. The retained input samples and the IPs were then resolved by SDS -PAGE, and B-Myb was detected by Western blotting (Figure 2 ). These results showed that a significant fraction of the input wt B-Myb was coimmunoprecipitated specifically with p107. BMybD205 -243 was also complexed to p107, albeit at lower levels, whereas in contrast none of the other BMyb deletion mutants was pulled down by p107 antibody (Figure 2) . Evidently, the specific ability of wt B-Myb and B-MybD205 -243 to abrogate the p107-mediated G1 block correlates with their capacity to complex with p107.
Transcriptionally activated C-terminally truncated B-Myb mutants fail to complex with p107 B-Myb transactivation activity is inhibited by p107 (Sala et al., 1996b) , suggesting that this protein might interact with the C-terminal NRD which negatively regulates B-Myb transcriptional activity (Bessa et al., 2001b) . To test whether the B-Myb NRD is implicated in p107 binding, plasmids encoding a series of Cterminally truncated B-Myb mutants (Bessa et al., 2001b) were transfected into U-2 OS cells together with an HA-epitope-tagged p107 plasmid. Immunoprecipitates collected with an anti-HA antibody were then Western blotted for B-Myb and p107. As expected, wt B-Myb co-immunoprecipitated with p107 in this experiment (Figure 3b ), however, it is remarkable that none of the C-terminally truncated mutants bound to p107. Removal of just 29 C-terminal aa (as in BMyb+675) was sufficient both to enhance transcriptional activity significantly ( Figure 3a ) and to abolish p107 binding ( Figure 3b ). Although this aspect was not further investigated in this study, these findings raise the possibility that wt B-Myb activity is regulated by endogenous p107 through an interaction involving the NRD.
The most transcriptionally active mutant in U-2 OS cells was found to be B-Myb+561 (Figure 3a) , and other experiments have shown it to be similarly hyperactivated in Saos-2 cells; thus, in a typical experiment B-Myb activated the pT811luc 3xA reporter by 1.5-fold in Saos-2 cells, whereas the reporter was activated 14-fold by B-Myb+561 (MB and RJW, unpublished data). It is particularly notable, therefore, that B-Myb+561 was found to have little effect on G1 arrest mediated by p107 in Saos-2 cells (Figure 3c ). These findings substantiate our contention that the ability of B-Myb to counteract p107-mediated G1 arrest does not reflect its transcriptional activity, rather it depends upon direct interaction between B-Myb and p107.
B-Myb interacts with an N-terminal domain of p107
It is known that p107 contains two domains which independently can block cell cycle passage in Saos-2 (input) were retained. The remainders were split into two fractions which were subjected to immunoprecipitation with either a p107 polyclonal antibody (p107 IP) or a control non-immune rabbit serum (Con IP). Inputs and IPs were run on the same SDS -PAGE gel and Western blots were probed with a B-Myb antibody cells (Zhu et al., 1995a) : one domain corresponds to the large pocket required for binding with E2F, while the other comprises an extensive N-terminal domain required for binding cyclin A2/cdk2 and cyclin E/cdk2 complexes. To map the binding site for B-Myb, interaction assays were performed using p107 deletion mutants in which these two activities are separated (N385 binds exclusively E2F, whereas C768 binds cyclin/cdk2). These p107 proteins were tagged with the 9E10 c-Myc epitope so that the same antibody could be used for immunoprecipitations, and it was evident that B-Myb interacted strongly with 9E10p107 and the 9E10C768 mutant but not with 9E10N385 ( Figure 4a ). We conclude that the B-Myb binding site on p107 overlaps that of cyclin/cdk2.
Inhibition of cyclin/cdk2 activity by p107 requires an N-terminal cyclin-interaction motif (ACRK; aa 66 -69), which is conserved in the related p130 protein (Castano et al., 1998) . Efficient binding of cyclin/cdk2 additionally requires a further motif (RRLF) located in the p107 spacer region. Deletion of the N-terminal 110 aa of p107 (mutant p107D110) or mutations to alanine within the ACRK motif (mutant p107AAA) abolished interactions with cyclin A2 and cyclin E (Castano et al., 1998) , however, binding was unaffected by deletion of only the N-terminal 10 aa (mutant p107D10). It was evident that binding of B-Myb to p107 was similarly unaffected by the p107D10 deletion, however, B-Myb interactions with the p107D110 and (a) Saos-2 cells were cotransfected with pcDNA3/B-Myb together with pcDNA3 expressing 9E10-epitope tagged wt p107 or the N385 or C768 mutants. Cell extracts were made 2 days posttransfection and 10% of the lysates (input) were retained. The remainder was immunoprecipitated with a 9E10 monoclonal antibody. Inputs and IPs were run on the same SDS -PAGE gel and Western blots were probed first with a B-Myb antibody and subsequently with the 9E10 antibody. (b) Saos-2 cells were cotransfected with pcDNA3/B-Myb together with pCMVp107 or pCMV vectors encoding the N-terminal mutants p107D10, p107D110 or p107AAA. Cell extracts were made 2 days posttransfection and 10% of the lysates (input) were retained. The remainder was immunoprecipitated with a p107 polyclonal antibody (p107IP). Western blots were probed first with a B-Myb antibody and subsequently with a p107 antibody. (c) Saos-2 cells were cotransfected with pcDNA3/B-Myb together with pcDNA3 encoding 9E10-epitope tagged p107, p130 or pRb. Cell extracts were made 2 days post-transfection and 10% of the lysates (input) were retained. The remainder was immunoprecipitated with a 9E10 antibody (9E10 IP), and Western blots were probed with a BMyb antibody Figure 3 B-Myb does not interact with transcriptionally activated C-terminally deleted mutants of B-Myb. The B-Myb mutants have been described previously (Bessa et al., 2001b) , and are truncated at the aa indicated (i.e. +675 extends from aa 1 -675, +561 extends from aa 1 -561 etc). (a) Transactivation activities of wt B-Myb and the B-Myb C-terminal mutants were compared by transfection of pcDNA3 expression vectors encoding these proteins together with the Myb-responsive luciferase reporter pT81luc 3xA into U-2 OS cells. Luciferase activities were assayed 2 days post-transfection and were corrected with respect to b-galactosidase activity directed by a cotransfected reporter. (b) Saos-2 cells were cotransfected with the empty pcDNA3 plasmid (vector) or pcDNA3 expressing wt B-Myb or the B-Myb Cterminal mutants together with pCMVp107HA. Cell extracts were made 2 days post-transfection and 10% of the lysates (input) were retained. The remainder was immunoprecipitated with an HA antibody (p107IP). Western blots were probed first with a BMyb antibody and subsequently with HA antibody. (c) Duplicate dishes of Saos-2 cells were transfected with the empty pcDNA3 vector, pcDNA3 encoding wt B-Myb or the C-terminally deleted mutant B-Myb+561, either with or without cotransfected pCMVp107. Cell cycle profiles were analysed as described in the legend to Figure 1 and the increase in G1 phase cells resulting from transfected p107 is represented by a bar chart In similar experiments with 9E10-epitope tagged p130 and pRB proteins (Figure 4c ), it was apparent that BMyb could interact with p130, but the affinity was much less than for p107. No interaction was seen with pRb.
B-Myb interacts with p107 and p107C768 in vitro
It is unclear from the in vivo binding studies whether the interaction between B-Myb and p107 is direct or requires an intermediate. To gain further insight into this question, B-Myb and p107 proteins were separately translated in a rabbit reticulocyte lysate in vitro, then mixed and subjected to co-immunoprecipitation analysis. By 35 S-labelling the proteins, it is apparent that B-Myb and 9E10-tagged p107, N385 and C768 proteins were successfully produced and immunoprecipitate in this system ( Figure 5) . B-Myb was coimmunoprecipitated with the 9E10 antibody in the presence of either p107 or the C768 mutant, however, no B-Myb was brought down when either unprogrammed lysate or the N385 mutant were used ( Figure  5 ). Although the involvement of a rabbit reticulocyte intermediate cannot be absolutely excluded, these results suggest that B-Myb binds directly to the p107 N-terminus.
The binding sites for B-Myb and cyclin A2 on p107 overlap
To determine whether the binding sites for B-Myb and cyclin A2 on p107 could be distinguished, binding assays comparing these proteins were carried out with the L series of p107 mutants (Zhu et al., 1995a) . As expected, cyclin A2 was found to bind L19 (aa 1 -781) and L20 (aa 1 -666), but removal of the RRLF spacer region motif in L30 (aa 1 -655) abolished cyclin A2 binding (Figure 6a) . In sharp contrast, B-Myb binding was unaffected by the L30 deletion, moreover, B-Myb bound equally well to the more extensively deleted L24 (aa 1 -584) and L23 (aa 1 -486) mutants. The minimal sequences required for B-Myb binding have yet to be defined, however, it is evident that these map entirely within an N-terminal domain which excludes the spacer region cyclin-binding motif (Figure 6b) . Nonetheless, cyclin A2 and B-Myb both require an N-terminal p107 sequence containing the ACRK motif for binding (Figure 4b) , and it is therefore likely that these proteins would compete for p107 interaction. Our findings indicate that the p107 N-terminus represents an additional transcription factor interaction domain which is distinct from the E2F-binding pocket ( Figure  6b) .
B-Myb and cyclin A2 binding to p107 is mutually exclusive
As their binding sites on p107 overlap, it seemed likely that B-Myb and cyclin A2 would compete for Figure 5 B-Myb and p107 interact in an in vitro system. A coupled rabbit reticulocyte in vitro transcription/translation system was used to make 35 S-methionine labelled B-Myb proteins and 9E10-epitope tagged p107, p107N385 and p107C768 proteins. The B-Myb protein was then mixed and incubated on ice with either unprogrammed lysate or the p107 proteins. Subsequently, the mixtures were subjected to immunoprecipitation with the 9E10 antibody and B-Myb was detected on a Western blot with a B-Myb antibody by ECL (film exposure time was 1 min) Figure 6 Interaction of B-Myb with p107 does not require the spacer region cyclin-binding motif. (a) U-2 OS cells were cotransfected with pcDNA3/B-Myb together with the empty pCMV vector (7) or pCMV encoding HA-tagged p107 mutants L19 (aa 1 -781), L20 (aa 1 -666), L30 (aa 1 -655), L23 (aa 1 -486) or L24 (aa 1 -584). Cell extracts were made 2 days post-transfection and 10% of the lysates (input) were retained, whilst the residues were immunoprecipitated with HA monoclonal antibody to pull down the p107 mutants. Inputs and IPs were run on the same SDS -PAGE gel and Western blots were probed first with a BMyb antibody and subsequently with HA and cyclin A2 antibodies. (b) Schematic diagram showing the domains of p107 required for interaction with E2F transcription factors, the adenovirus E1A, SV40 T antigen and HPV16 E7 protein, cyclin A2/cdk2 and B-Myb
Interaction of B-Myb with p107 M Joaquin et al interaction with this N-terminal domain. Such competition may prevent inhibition of cyclin A2/cdk2 activity by p107 in the presence of excess B-Myb, thereby providing an explanation for the reversal of p107-mediated G1 arrest in cells co-transfected with B-myb. To determine whether B-Myb and cyclin A2 are present in mutually exclusive complexes with p107, reciprocal co-immunoprecipitations were carried out using B-Myb and cyclin A2 antibodies. U-2 OS cells were used for these experiments, as in contrast to Saos-2 cells they contain sufficient endogenous cyclin A2 to allow ready detection of complexes. The cells were cotransfected with plasmids encoding an HA epitopetagged p107 alone (p107HA) or a combination of both p107HA and B-Myb. It is clear that B-Myb antibodies efficiently co-immunoprecipitated p107, however, no cyclin A2 was present in these IPs (Figure 7a) . Conversely, cyclin A2 antibodies efficiently co-immunoprecipitated p107HA, however, B-Myb was not brought down ( Figure 7b ). Unexpectedly, co-transfection of B-Myb had no discernible effect on the quantity of p107HA co-immunoprecipitated with cyclin A2 (Figure 7b ), and reciprocal experiments using an HA antibody similarly showed little effect of B-Myb expression on cyclin A2 co-immunoprecipitation with p107 (data not shown). Furthermore, using either in vitro or in vivo assays we were unable to show consistently that B-Myb could overcome inhibition of cyclin A2 kinase activity by p107 (data not shown). It may be concluded that although B-Myb and cyclin A2 form mutually exclusive complexes with p107, the interaction of cyclin A2 cannot be competed under experimental conditions by B-Myb. It remains a formal possibility that in certain cell compartments or protein complexes B-Myb may act to prevent sequestration of cyclin A2 kinase activity.
B-Myb enhances cyclin E kinase activity
As for cyclin A2/cdk2, cyclin E/cdk2 activity is also inhibited by the p107 cyclin-binding domain (Zhu et al., 1995a) . It was noted, however, that cyclin E is more efficient than cyclin A2 in rescuing growth suppression induced by p107 (Zhu et al., 1995a) , and we reasoned therefore that suppression by B-Myb of p107's cdk inhibitory activity may be more readily observed with cyclin E. To test whether B-Myb had effect upon cyclin E kinase activity, plasmids encoding B-Myb, 9E10 epitope-tagged cyclin E and cdk2 were cotransfected into Saos-2 cells and in vitro kinase assays were carried out on 9E10 immunoprecipitates using histone H1 as a substrate. Cyclin E/cdk2 activity was found to be modestly but consistently enhanced by B-Myb cotransfection in these experiments (Figure 8 ).
Figure 7 B-Myb and cyclin A2 form mutually exclusive complexes with p107. U-2 OS cells were transfected with expression plasmids encoding HA epitope-tagged p107 (p107HA) and BMyb as indicated. Extracts were made 2 days post-transfection and 10% was retained (Input). The remainder was split into two fractions and subjected to IP with either a B-Myb (a) or a cyclin A2 (b) antibody. Inputs and immunoprecipitates were Western blotted and transfected p107 and B-Myb were detected with an HA antibody and a B-Myb antibody, respectively. The positions of the p107HA and B-Myb bands are indicated with arrowheads. A non-specific band running just below B-Myb which was detected with the B-Myb antibody in the B-Myb immunoprecipitates is indicated with an asterisk. The blots were subsequently probed with a cyclin A2 antibody to detect endogenous cyclin A2 which was associated with the other proteins, and the position of the cyclin A2 band in (b) is indicated with an arrowhead. The asterisk marks an immunoglobulin band in (a) Figure 8 B-Myb enhances cyclin E kinase activity. (a) Saos-2 cells were transfected with a control empty pcDNA3 vector (Con) or either 0.25 or 1 mg of a 9E10 epitope-tagged cyclin E expression plasmid together with a cdk2 plasmid (2.5 mg). As indicated, transfections also contained either 10 mg pcDNA3/B-Myb or the empty vector. Extracts were made with RIPA buffer 2 days post-transfection and cyclin E was immunoprecipitated with 9E10 antibody. Immunoprecipitates were subjected to an in vitro kinase assay using histone H1 as a substrate. The radioactively labelled H1 was separated on a 14% SDS -PAGE gel and detected by autoradiography. At top, a typical result is shown, whilst below results from four separate experiments are represented graphically. (b) Similar experiments were done at plasmid inputs of 0.25 mg cyclin E/2.5 mg cdk2 and either 5, 10 or 15 mg or pcDNA3/ B-Myb. The graph represents results from three separate experiments
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M Joaquin et al Thus, at two different cyclin E plasmid inputs, B-Myb co-expression induced kinase activity by greater than two-fold (Figure 8a) , and the fold induction in cyclin E kinase activity could be further enhanced at a higher BMyb input (Figure 8b ). Although these findings are consistent with the notion that B-Myb prevents cyclin E/cdk2 activity from inhibition by endogenous p107, we were unable to show consistently that B-Myb could counteract inhibition of this kinase activity in in vitro assays when p107 was cotransfected (data not shown). However, suppression of the inhibitory effect of p107 by B-Myb could be observed using an in vivo assay in which phosphorylation of a cyclin E/cdk2 substrate (a Cterminal fragment of Rb, C792 -928) was assessed in transfected cells by Western blotting with a phosphospecific antibody (Figure 9 ). In this assay, transfected B-Myb was found to enhance phosphorylation of Rb C792 -928 by cyclin E/cdk2 in the absence of cotransfected p107, consistent with the results shown in Figure 8 . Cyclin E/cdk2 activity was progressively inhibited by the p107 L20 mutant at moderate and high input (2 and 8 mg plasmid), however, B-Myb maintained enhanced kinase activity in cells cotransfected with the moderate p107 L20 input, (Figure 9 ). At high p107 L20 input, the effect of B-Myb was negligible. This experiment demonstrates that under the appropriate conditions, expression of B-Myb is able to maintain high levels of cyclin E/cdk2 activity in the face of p107, and therefore potentially suppress the effects of p107 on cell growth.
Discussion
We have shown here that the ability of B-Myb to overcome a G1 block imposed by p107 correlates precisely with a strong physical interaction between these proteins rather than with B-Myb transactivation function. In contrast to a previous report that described an interaction between B-Myb and the Cterminal pocket domain of p107 (Sala et al., 1996b) , we found that B-Myb interacts with an N-terminal region of p107 that overlaps a cyclin E/cdk2 and cyclin A2/ cdk2 inhibitory domain. We have no explanation for this discrepancy, but note that both our in vivo and in vitro binding studies (Figures 4, 5 and 6 ) are in support of an N-terminal interaction.
Both the N-terminal domain of p107 and the RRLF spacer region motif are required for high affinity interactions with cyclin/cdk2 as well as for G1 arrest in Saos-2 cells (Castano et al., 1998) . It is notable that the RRLF motif is completely dispensable for the BMyb/p107 interaction (Figure 6 ), moreover, B-Myb retained some very limited residual binding to p107D110, in which the N-terminal cyclin-binding motif is deleted (Figure 4b ). It is evident, therefore, that the binding sites for cyclins and B-Myb on p107 overlap but are not identical. This conclusion presumably explains why p130, which binds cyclins with similar affinity to p107 (Woo et al., 1997) , interacts only weakly with B-Myb (Figure 4c ).
Although our findings suggest that B-Myb overcomes a p107-mediated G1 block by preventing p107 from sequestrating cyclin A2 and cyclin E kinases, we were unable to show that B-Myb competed directly for the overlapping binding site on p107. Nonetheless, our data clearly show that the binding of cyclin A ( Figure  7 ) and cyclin E (data not shown) to p107 is mutually exclusive with respect to B-Myb. Moreover, we were able to show that cotransfection of B-Myb stimulated cyclin/cdk2 activity ( Figure 8 ) and maintained cyclin E/ cdk2 kinase activity in cells cotransfected with moderate amounts of a plasmid encoding the p107 cyclin-binding domain (Figure 9 ). Further evidence that abrogation of the p107 cell cycle block by B-Myb reflects counteraction of the cyclin/cdk inhibitory activity of p107 has been provided by our finding that B-Myb overcomes cell inhibition imposed by the p107C768 mutant (MB and RJW, unpublished data), which appears to act solely through binding cyclin/ cdk2 complexes (Zhu et al., 1995b) . Overall, our data are consistent with B-Myb having effects on the cell cycle through a mechanism independent of its transactivation properties.
G1 arrest of Saos-2 cells by p107 results from inhibition of E2F activity in addition to effects on cyclin/cdk2 (Zhu et al., 1995a) , implying that B-Myb must prevent growth suppression by both mechanisms. E2F-4 complexes containing both cyclin A2/cdk2 and p107 can readily be detected during S phase by electrophoretic mobility shift analysis, and the majority of this complex appears to be cytoplasmic and presumably transcriptionally inert (Verona et al., 1997) . The existence of these complexes illustrates that p107 can interact simultaneously with distinct proteins occupying the pocket and the N-terminal cyclinbinding domain, however, our initial cotransfection Figure 9 B-Myb partially overcomes inhibition of cyclin E/cdk2 activity by the p107 cyclin-binding domain. Saos-2 cells were transfected as indicated with plasmids encoding a C-terminal Rb C792-928 fragment (4 mg), cyclin E plus cdk2 (2 mg each), B-Myb (10 mg) and moderate or high amounts of the p107 L20 protein containing the cyclin-inhibitory domain (2 or 8 mg). Protein extracts obtained 2 days post-transfection were subjected to Western blotting using a phospho-specific (S807/S811) Rb antibody (Cell Signaling Technology #93085) to detect in vivo modification of the Rb C792-928 substrate by cyclin E/cdk2. Expression of the other proteins was confirmed using the appropriate antibody studies indicate that B-Myb does not enter E2F-4/DP-1 DNA-binding complexes with p107 (RJW, unpublished data). Further studies are therefore required to determine how B-Myb counteracts p107's effect on E2F activity.
The genes encoding B-Myb and p107 are temporally coregulated during the cell cycle under E2F transcriptional control (Hurford et al., 1997; Lam et al., 1992; Zhu et al., 1995b) . Induction of B-Myb expression in late G1 phase could, therefore, act at that stage of the cell to prevent newly synthesized p107 from inhibiting entry into S phase. Although it is likely that p107 is more abundant than B-Myb in most cell types, p107 exists in distinct phosphorylated forms and is distributed between cytoplasmic and nuclear fractions (Verona et al., 1997) . Under normal physiological conditions, levels of B-Myb could therefore be sufficient at the G1/S transition to overcome the inhibitory effects of a specific p107 fraction. It is notable that B-Myb is highly expressed in embryonal stem (ES) cells, and evidence points to an essential role for B-Myb in these cells (Tanaka et al., 1999) . By coimmunoprecipitation experiments, we have found that a large proportion of p107 is associated with BMyb in ES cells (MJ and RJW, unpublished data) , suggesting that this interaction may contribute to the functional requirements for B-Myb in early development.
A number of studies have described specific interactions of p107 with transcription factors other than E2F and B-Myb, such as c-Myc (Beijersbergen et al., 1994) , Sp1 (Datta et al., 1995) and C/EBPa (Timchenko et al., 1999) . Whilst c-Myc interacts with the p107 pocket domain and is clearly quite different in this respect to B-Myb, Sp1 transcriptional activity was found to be inhibited by either wt p107 or the p107DE mutant, which lacks much of the pocket domain including the spacer region (Datta et al., 1995; Zhu et al., 1993) . Although an in vivo association with Sp1 was demonstrated only with wt p107 (Datta et al., 1995) , these functional data suggest that B-Myb and Sp1 interact with a similar region of p107. The N-terminus of p107 may therefore comprise a novel domain which regulates the activity of transcription factors which play key roles in controlling cell proliferation and differentiation.
The human cytomegalovirus immediate -early protein IE1-72 has also been shown to interact with an N-terminal domain of p107, and like B-Myb is capable of reversing G1 arrest mediated by p107 in Saos-2 cells (Johnson et al., 1999a) . In view of our finding that B-Myb interacted only weakly with p130 ( Figure 4c ) it is of interest that p130/IE1-72 interactions could not be demonstrated (Johnson et al., 1999a) . Overall, it is apparent that there are certain parallels between the activities of B-Myb and IE1-72. Although the specific role of IE1-72 in cytomegalovirus replication is unclear, it is of note that human cytomegalovirus infection disrupts normal cell proliferation leading to a state which is presumed to favour virus DNA replication (Jault et al., 1995) .
In addition to its effects on p107, B-Myb has also been reported to overcome a cell proliferation block imposed by p53 in the T98G glioblastoma cell line derivative GM47.23 (Lin et al., 1994) . Induction of p53 resulted in transcriptional up-regulation of the cyclindependent kinase inhibitor p21
Waf1/Cip1 , which inhibits cyclin E/cdk2 and cyclin A2/cdk2 activities in a similar manner to the N-terminal domain of p107. Notably, a transcriptionally inactive B-Myb mutant (BMyb.MUT7: deletion of aa 207 -268) could partially overcome a p53 cell cycle block in Saos-2 cells (Lin et al., 1994) , and it is significant that this deletion overlaps that in B-MybD205 -243 which we show can overcome a p107 G1 arrest (Figure 1 ). These similarities suggest that the B-Myb functions required to bypass the p53/p21
Waf-1/Cip1 and p107 cell cycle blocks are related, if not identical. We have recently observed that B-Myb is able to interact in vitro with p21
Waf-1/Cip1
, although no interaction was seen in vivo (MJ and RJW, unpublished data), and these findings will prompt further experiments to test whether cell cycle promotion by B-Myb may reflect effects upon a larger group of cdk inhibitors.
A previous study indicated that p107 inhibits B-Myb transcriptional activity (Sala et al., 1996b) , suggesting that binding of these proteins mutually suppresses their functions. It should be noted, however, that B-Myb is positively regulated by cyclin A2/cdk2-mediated phosphorylation (Bessa et al., 2001b) , and suppression of BMyb transactivation by p107 may result from its cyclin/cdk2 inhibitory activity rather than a direct interaction. Nonetheless, it is intriguing that transcriptionally activated B-Myb mutants with deletions in the C-terminal have all lost the ability to bind p107 ( Figure  3 ). The influence of the B-Myb NRD, which maps to this C-terminal region, can be overcome in some respects by cyclin A2/cdk2 phosphorylation (Bessa et al., 2001b) , however, we have been unable to find any evidence that this modification affects the B-Myb/p107 interaction (MJ and RJW, unpublished data). Thus it seems unlikely that the function of the B-Myb NRD is simply contingent upon p107 binding.
B-Myb has an essential role during embryogenesis (Tanaka et al., 1999) and is also implicated in regulating cell cycle exit during differentiation of certain haematopoietic cells (Bies et al., 1996; Engelhard et al., 2000; Golay et al., 1997) . In light of our current findings, it will be of interest to explore the contribution made by the B-Myb/p107 interaction to these cellular processes.
Materials and methods
Plasmids
Deletions were introduced into B-Myb AR coding sequences by PCR using Pfu DNA polymerase (Promega). Mutated sequences were checked by DNA sequencing for polymerasemediated errors, then were used to replace wt sequences in the B-Myb expression plasmid, pcDNA3/B-myb (Saville and Watson, 1998b) . Generation of the C-terminal deleted B-Myb mutants has been described (Bessa et al., 2001b) . Expression plasmids encoding wt p107, p107HA and the N385, C768 and L series mutants were obtained from Dr Liang Zhu (Zhu et al., 1993) , whilst p107D10, p107D110 and p107AAA were obtained from Dr Brian Dynlacht (Castano et al., 1998) . The 9E10 epitope tagged pocket protein expression plasmids were generated by modifying the N-terminal coding sequences using PCR such that the first methionine codon was replaced with a BamHI site. These sequences were then subcloned in a modified pcDNA3 vector which encodes an N-terminal 9E10 epitope (MEQKLISEEDLNMA) immediately upstream of a BamHI cloning site. Expression vectors (pCMX) encoding 9E10-epitope-tagged cyclin A2 and cyclin E were obtained from Dr Jonathan Pines. A pcDNA3 expression vector encoding a 9E10-epitope tagged Rb C792-928 fragment was obtained from Dr Sybille Mittnacht.
Transfections and reporter gene assays
The human osteosarcoma cell lines Saos-2 and U-2 OS were maintained in Dulbecco's modified Eagle's medium containing 10% foetal calf serum. Cells at 50% confluence were transfected using the calcium phosphate precipitation technique as described previously (Lane et al., 1997) . The precipitate was left overnight on U-2 OS cells but was washed off Saos-2 cells after 8 h. Luciferase and bgalactosidase assays were performed as described .
Cell cycle analyses
Saos-2 cells seeded at 50% confluency on 10 cm dishes were transfected with 30 mg plasmid DNA in total comprising, as appropriate, 10 mg pcDNA3/B-myb (or mutants of B-Myb), 10 mg pCMVp107 (or mutants of p107) and 2 mg of pCMVCD20 (encoding the CD20 cell surface protein) by exposure to calcium phosphate co-precipitates for 8 h. Cells were detached 2 days post-transfection by washing with 3 mM EDTA in PBS, then stained with FITC-labelled CD20 antibodies (Becton-Dickinson). After overnight fixation at 48C with 70% ethanol, cells were stained in PBS containing 18 mg/ml propidium iodide and 8 mg/ml RNase A for 30 min at room temperature in the dark. Transfected CD20 positive cells were discrimated from untransfected cells by flow cytometry with a Becton-Dickinson FACSort using the FL1 channel, and cell cycle profiles were obtained and quantified in the FL2A channel using FlowJo software.
Co-immunoprecipitation assays
Transfected cells were washed with ice-cold PBS and scraped into 500 ml IP buffer (50 mM HEPES, pH 7.5, 220 mM NaCl, 0.5% NP40, 5 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 10 mM b-glycerophosphate, 2 mM Na 3 VO 4 , 5 mM benzamidine, 1 mM dithiothreitol, containing the recommended concentration of a protease inhibitor cocktail (Roche). The lysates were cleared by microcentrifugation and then further cleared by addition of 50 ml protein G beads (50% slurry in IP buffer; Pharmacia). Antibodies were added to the cleared lysates for 2 h on ice, then 50 ml protein G beads were added and continuously mixed for a further 2 h. Immune complexes were collected by brief microcentrifugation and washed rapidly three times with IP buffer. Immunoprecipitates and samples of the input lysates were subjected to Western blotting as described (Saville and Watson, 1998b) . The antibodies used for these analyses were a rabbit B-Myb polyclonal (Santa Cruz N-19), a rabbit p107 polyclonal (Santa Cruz C-18), the mouse 9E10 monoclonal (Santa Cruz), a rabbit cyclin A2 polyclonal (Santa Cruz H-432) and a mouse HA.11 monoclonal (BAbCO).
In vitro translation and protein association assays
Proteins were synthesized in a coupled T7 RNA polymerase/ rabbit reticulocyte lysate transcription/translation system (TNT, Promega) and labelled with 35 S-methionine. Proteins were allowed to associate by mixing the programmed reticulocyte lysates and incubating at 308C for 30 min. Immunoprecipitations were carried out with 9E10 antibody after dilution with 500 ml IP buffer and Western blots were developed with B-Myb antibody and ECL reagents; film exposure was limited to 1 min to avoid background from the radioactively labelled proteins.
In vitro kinase assays
Lysates were prepared using RIPA buffer from Saos-2 cells transfected with plasmids specifiying 9E10 epitope-tagged cyclin E or cyclin A2 (the gifts of Jonathon Pines) and either B-Myb or an empty vector. Immunoprecipitations were carried out using 9E10 antibody coupled to protein G beads through a secondary anti-mouse IgG antibody (Sigma). After three washes with IP buffer, histone H1 kinase assays were performed as described previously (Pines and Hunter, 1989) .
